Equity Overview
Price & Market Data
Price: $20.00
Daily Change: -$1.94 / 9.70%
Daily Range: $20.00 - $22.18
Market Cap: $547,935,680
Daily Volume: 150,831
Performance Metrics
1 Week: -3.61%
1 Month: 23.65%
3 Months: 38.60%
6 Months: 33.48%
1 Year: 45.60%
YTD: 5.18%
Company Details
Employees: 74
Sector: Health technology
Industry: Biotechnology
Country:
Details
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.